Search Results
Your search for all items matches 35151 pages
Showing 9651 - 9700Balancing a Reverence for Life With a Belief That Patients Have a Right to a Dignified Death
The U.S. right-to-die movement took root in the mid-1970s, when Derek Humphry helped his wife, who was dying of breast cancer, take her own life. Five years later, Mr. Humphry founded the Hemlock Society, the first right-to-die organization in the United States,1 and set off a firestorm of...
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
On March 26, 2021, idecabtagene vicleucel was approved for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.1,2 Idecabtagene vicleucel is...
An Epiphany During Fellowship Led to a Career in Geriatric Oncology for Heidi D. Klepin, MD, MS
Geriatric oncologist Heidi D. Klepin, MD, MS, was born and reared in Pearl River, a hamlet on the west side of the Hudson River in New York. “My parents are German immigrants who came to the United States in the 1960s looking for prospects. Growing up in post-war Germany, neither had the...
American Academy of HIV Medicine Names Leslie McGorman, MPPA, as Director of Public Policy
The American Academy of Human Immunodeficiency Virus (HIV) Medicine recently announced the appointment of Leslie McGorman, MPPA, as its new Director of Public Policy. A seasoned professional in both federal and state government affairs, Ms. McGorman possesses 20 years of health policy experience...
AUA Names 2021 Award Recipients
Each year, the American Urological Association (AUA) honors the contributions of physician researchers and educators in the field of medicine, the specialty of urology, and the organization. The following individuals are the 2021 honorees: Ian M. Thompson Jr, MD, Ramon Guiteras Award, for...
Refining Cardiovascular Risk Assessment in Childhood Cancer Survivors
There are an estimated 500,000 childhood cancer survivors in the United States, a number that will increase exponentially in the coming years. Over half of all childhood cancer survivors will have received cardiotoxic therapies during primary cancer treatment or relapse. For these survivors, there...
Improving Prediction of Risk for 10-Year Left-Ventricular Systolic Dysfunction in Survivors of Childhood Cancer
In a Dutch study reported in JACC: CardioOncology, Jan M. Leerink, PhD candidate, of Amsterdam UMC, University of Amsterdam Department of Clinical and Experimental Cardiology, and colleagues found that the addition of ejection fraction measurement at the time of first surveillance echocardiogram...
Sloan Kettering Institute Researchers Awarded 2021 Kravis Women in Science Endeavor Fellowship Grants
Memorial Sloan kettering Cancer Center (MSK) announced that Sloan Kettering Institute (SKI) researchers Regina Bou Puerto and Mijin Kim, PhD, have been named 2021 Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grant recipients. The Kravis WiSE initiative, created in 2020,...
Celebrating 50 Years of Cancer Progress: The International View
Although the National Cancer Act of 1971 has resulted in tremendous advances in cancer research, which have led to sharp declines in cancer mortality in the United States—from 1991 to 2018, there has been a 31% decrease in overall cancer death rates—and more than 17 million cancer survivors,1 much...
St. Jude Children’s Research Hospital Announces Its Largest Strategic Expansion
St. Jude Children’s Research Hospital is launching the biggest strategic investment in its nearly 60-year history, committing $11.5 billion during the next 6 years to accelerate research and treatment globally for children with catastrophic diseases. The Six-Year St. Jude Strategic Plan focuses on...
Roswell Park, Wilmot Cancer Institute Collaborate in Study of Immunotherapy for Black Patients With Cancer
A NEW COLLABORATION between two Western New York cancer research leaders will help oncologists learn whether Black and White patients with cancer respond differently to immunotherapy and seek to improve the safety and effectiveness of these newer drugs in diverse populations. Funded by a 2-year,...
Nima Sharifi, MD, Receives 2021 AACR–Waun Ki Hong Award in Translational and Clinical Cancer Research
THE AMERICAN ASSOCIATION for Cancer Research (AACR) has recognized Nima Sharifi, MD, with the 2021 AACR–Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. Dr. Sharifi is Director of the Center for Genitourinary Malignancies Research at Lerner Research...
Ton Schumacher, PhD, FAACR, Receives 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology
THE AMERICAN ASSOCIATION for Cancer Research (AACR) recognized Ton Schumacher, PhD, FAACR, with the 2021 AACR-CRI Lloyd J. Old Award in Cancer Immunology during the virtual AACR Annual Meeting 2021 in April. The award recognizes an active scientist whose outstanding and innovative research has made ...
Stand Up To Cancer Funds $6 Million for Disparities in Cancer Clinical Trials Research
STAND UP TO CANCER® (SU2C) has awarded $6 million to a multi-institutional team headed by Mount Sinai researchers to collaborate with other New York institutions in an initiative that addresses disparities in cancer clinical trials participation by patients who are Black, indigenous, and people of...
First-Line Nivolumab Plus Cabozantinib Improves Progression-Free and Overall Survival vs Sunitinib in Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and...
Fam-trastuzumab Deruxtecan-nxki for Trastuzumab-Pretreated Advanced HER2-Positive Gastric Adenocarcinoma
On January 15, 2021, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was approved for treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma who have received a prior trastuzumab-based regimen.1,2 Supporting Efficacy Data...
EMPOWER-Lung 1 Trial: New Options, No New Answers
The EMPOWER-Lung 1 trial, recently reported in The Lancet and reviewed in this issue of The ASCO Post, showed an improvement in progression-free and overall survival with cemiplimab-rwlc in patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression (tumor proportion score...
First-Line Cemiplimab-rwlc Improves Outcomes vs Platinum-Doublet Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 50%
As reported in The Lancet by Ahmet Sezer, MD, of Başkent University, Adana, Turkey, and colleagues, the phase III EMPOWER-Lung 1 trial has shown improved overall and progression-free survival with cemiplimab-rwlc vs platinum doublet chemotherapy among patients with advanced non–small cell lung...
FDA ODAC Meeting Focuses on ‘Dangling’ Accelerated Approvals of Anti–PD-1/PD-L1 Antibodies
In a perspective in The New England Journal of Medicine, Julia A. Beaver, MD, and Richard Pazdur, MD, of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE), discussed issues surrounding “dangling” accelerated approvals of anti–PD-1/PD-L1 antibodies—ie, approvals for...
Narjust Duma, MD, and Gladys I. Rodriguez, MD, on A First for Hispanic Women: Formation of a YIA for Latinas
Narjust Duma, MD, of the Carbone Cancer Center at the University of Wisconsin, Madison, and Gladys I. Rodriguez, MD, of South Texas Oncology and Hematology, talk about the underrepresentation of Hispanic individuals in medicine, especially in oncology, and their efforts to create the first Young...
Inequities in Breast Cancer Screening During the COVID-19 Pandemic
Breast cancer screening took a sizeable hit during the COVID-19 pandemic, according to new research showing that the number of screening mammograms completed in a large group of women living in Washington state plummeted by nearly half. Published by Amram et al in JAMA Network Open, the study...
ASCO Issues Guideline on Dyspnea in Advanced Cancer
ASCO has issued a new guideline on the clinical management of dyspnea in adult patients with advanced cancer.1 Dyspnea—or breathlessness—is a common and distressing symptom affecting upward of 70% of patients with advanced cancer.2 “Dyspnea is a highly prevalent symptom, particularly when people...
ASCO Honors 2021 Special Awards Recipients
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of ASCO’s Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation. “The...
Drive, Curiosity, and a Love of Science: One Nurse’s Road to a Leadership Role in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Deborah Watkins Bruner, RN, PhD, FAAN, noted for her work in patient-reported outcomes, symptom management, and comparative effectiveness of radiotherapy modalities. Her current research is focused on...
Fluciclovine F-18 PET/CT vs Conventional Imaging Alone in Guiding Postsurgery Salvage Radiotherapy for Prostate Cancer
In a single-institution phase II/III trial (EMPIRE-1) reported in The Lancet, Ashesh B. Jani, MD, and colleagues found that use of fluciclovine F-18 positron-emission tomography/computed tomography (PET/CT) in addition to conventional imaging to guide postprostatectomy salvage radiotherapy was...
Enfortumab Vedotin-ejfv After PD-1 or PD-L1 Inhibitor Therapy for Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
As reported in The Lancet Oncology by Evan Y. Yu, MD, and colleagues, findings in a cohort of the phase II EV-201 study showed a high response rate with the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv in cisplatin-ineligible patients with advanced or metastatic urothelial...
Does Long-Term Suppression of Hepatitis B in Patients With HIV Lower Risk of Hepatocellular Carcinoma?
While the risk of hepatocellular carcinoma (HCC) is higher among patients who have human immunodeficiency virus (HIV), it’s even higher among patients who have HIV and detectable hepatitis B, according to research published by Kim et al in Hepatology. Among patients with HIV and hepatitis B,...
Cognitive Performance at Baseline and Over Time in Infants Treated for Brain Tumors
In a prospective longitudinal trial reported in the Journal of Clinical Oncology, Ali et al found that infants treated for central nervous system (CNS) malignancies had baseline intellectual quotient (IQ) and parent-reported working memory and adaptive functioning worse than normative expectations; ...
Machine Learning–Based Algorithm May Predict Short-Term Mortality in Patients With Cancer and Prompt Serious Illness Conversations
Although most patients with terminal cancer, 87%, have end-of-life conversations with clinicians about their goals and preferences for care, on average, these discussions happen just 1 month before death and most often occur in acute care settings with clinicians who are not their treating...
Oral Azacitidine Improves Overall Survival vs Placebo as Maintenance Therapy for AML in First Remission
As reported in The New England Journal of Medicine by Andrew H. Wei, MB, BS, PhD, of the Australian Centre for Blood Diseases, Monash University, Melbourne, and colleagues, the phase III QUAZAR AML-001 trial has shown prolonged overall survival with oral azacitidine maintenance therapy vs placebo...
Pembrolizumab as Long-Term Treatment Option in Relapsed or Refractory Classical Hodgkin Lymphoma
For patients with relapsed or refractory classic Hodgkin lymphoma (HL), salvage chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) is the standard of care and can induce long-term remissions in at least 60% of patients.1,2 Patients with progression of disease after...
Pembrolizumab Improves Progression-Free Survival vs Brentuximab Vedotin in Relapsed or Refractory Classic Hodgkin Lymphoma
As reported in The Lancet Oncology by John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, an interim analysis of the phase III KEYNOTE-204 trial has shown significantly improved progression-free survival with pembrolizumab vs brentuximab vedotin in patients with...
2021 Genitourinary Cancers Symposium: Advancements in the Care of Older Adults With Prostate Cancer
The 2021 Genitourinary (GU) Cancers Symposium was held in a virtual format on February 11–13 and featured the latest developments in the understanding and treatment of genitourinary cancers. The impact of prostate cancer therapies on outcomes in older adults continues to be a growing area of...
Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 26, 2021, the peptide-conjugated alkylating...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 26th Annual Conference, which was held virtually...
Douglas R. Lowy, MD, FAACR, Honored With 2021 AACR–Margaret Foti Award
The American Association for Cancer Research (AACR) presented Douglas R. Lowy, MD, FAACR, with the 2021 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the virtual AACR Annual Meeting 2021. Dr. Lowy is Chief of the Laboratory of Cellular Oncology,...
FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic EGFR Exon 20 Insertion–Mutated NSCLC
On May 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor and MET receptors, for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and...
AACR Announces Recipients of 2021 Scientific Achievement Awards and Lectureships
The American Association for Cancer Research (AACR) honored a number of cancer researchers, physician-scientists, advocates, and policymakers for their achievements during week 1 of the virtual AACR Annual Meeting 2021 (April 10–15, 2021). Several of these recipients were mentioned in previous...
AACR to Recognize the St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team With 2021 Team Science Award
The American Association for Cancer Research (AACR) will recognize the St. Baldrick’s Foundation–Stand Up To Cancer (SU2C) Pediatric Cancer Dream Team with the 2021 AACR Team Science Award. In early 2013, the St. Baldrick’s Foundation and SU2C collaborated to create a Pediatric Cancer Dream Team...
Expert Point of View: Patrick Y. Wen, MD
“This study is interesting, and the results were a little surprising,” said Patrick Y. Wen, MD, Professor of Neurology at Harvard Medical School and Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. “The prognosis of these tumors in children and adolescents is so terrible...
Oncolytic Virotherapy Achieves Early Signs of Success in High-Grade Gliomas
Treatment with genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) G207 alone or with radiation resulted in encouraging outcomes in a small study of pediatric patients with high-grade glioma. In a phase I trial, responses were observed in 11 of 12 children, and median overall...
Expert Point of View: Ezra E.W. Cohen, MD
Formal discussant of the -LIBRETTO-001 trial, Ezra E.W. Cohen, MD, Associate Director for Translational Science and Leader of the Solid Tumor Therapeutics Research Program at the Moores Cancer Center at UC San Diego Health, was encouraged by this trial and said that detection of genetic...
Selpercatinib Makes Inroads in Other RET Fusion–Positive Tumor Types
The selective RET inhibitor selpercatinib is now approved for RET fusion–positive lung and thyroid cancers. New evidence presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting 2021 shows that selpercatinib is active against other RET fusion–positive...
Lisa M. Coussens, PhD, FAACR, Elected AACR President-Elect for 2021–2022
The members of the American Association for Cancer Research (AACR) have elected Lisa M. Coussens, PhD, FAACR, as their President-Elect for 2021–2022. She started her official role as President-Elect on April 12, 2021, during the AACR’s Business Meeting of Members and will assume the Presidency in...
New President and Executive Council Officers for the Society of Surgical Oncology
The Society ofSurgical Oncology (SSO) recently announced its 2021–2022 elected Executive Council Officers, including its new President, Douglas S. Tyler, MD, MSHCT, FSSO. Dr. Tyler currently holds the John Woods Harris Distinguished Chair in Surgery at The University of Texas Medical Branch in...
2021 ASCO Annual Meeting: Data From a Premeeting Presscast
The 2021 ASCO Annual Meeting kicked off this week with a premeeting presscast, where data from five studies to be presented at the conference were discussed. On this podcast, we’ll hear from two authors featured in that presscast about findings in non–small cell lung cancer and the effect of...
FDA Pipeline: Applications Accepted for Marginal Zone Lymphoma and Lung Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to zanubrutinib in pretreated patients with marginal zone lymphoma, and accepted a biologics license application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line...
Reduced-Intensity Oxaliplatin/Capecitabine for Older and Frail Patients With Advanced Gastroesophageal Cancer
In the phase III GO2 trial reported in JAMA Oncology, Hall et al found that reduced-intensity oxaliplatin/capecitabine was associated with improved patient experience, reduced toxicity, and noninferior progression-free survival compared with higher-intensity treatment among older and frail patients ...
Expert Point of View: Jamie N. Bakkum-Gamez, MD
The invited discussant of the studies, Jamie N. Bakkum-Gamez, MD, Professor of Obstetrics and Gynecology and Co-Lead of the Women’s Cancer Program at Mayo Clinic Cancer Center, Rochester, Minnesota, first reminded attendees of the scope of the problem: an estimated 40% or so of women slated for...
Ipilimumab Plus Anti–PD-1 Therapy vs Ipilimumab Alone for Patients With Advanced Melanoma Resistant to Anti–PD-1/PD-L1 Monotherapy
In a retrospective cohort study reported in The Lancet Oncology, da Silva et al found that better outcomes were achieved with the combination of an anti–PD-1 agent plus ipilimumab vs ipilimumab alone in patients with advanced melanoma who were resistant to prior anti–PD-1 or anti–PD-L1 ...
